Evidence map›Paper›PMID 19381301›Full record

ArticlePloS one2009

Chronic granulomatous disease: the European experience.

J Merlijn van den Berg, Elsbeth van Koppen, Anders Ahlin, Bernd H Belohradsky, Ewa Bernatowska, Lucien Corbeel, Teresa Español, Alain Fischer, Magdalena Kurenko-Deptuch, Richard Mouy and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03983837 (Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease), which is not on this map. Cited by 293 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03983837 phase2completednot on this mapstarted 2021, after this paper: background citation

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2021 to 2025Enrolled3ConditionsChronic Granulomatous Disease, Inflammatory Bowel DiseaseArmsNeocate Splash
3 · Its place in the literature

Who cites it

293 citing papers in PubMed, 2 syntheses or guidelines pooled it, 678 citations in OpenAlex.

  1. Pooled it
  2. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Guideline
  3. Prime Editing for p47The New England journal of medicine · 2026
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. A roadmap to chemically reactive species: how diverse oxidants affectMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. The Role of NADPH Oxidase 2 in Leukocytes.Antioxidants (Basel, Switzerland) · 2025
    Review
  20. Review

233 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 11 countries.

J Merlijn van den BergSanquin Research, and Landsteiner Laboratory, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. j.m.vandenberg@amc.nl
Elsbeth van Koppen
Anders Ahlin
Bernd H Belohradsky
Ewa Bernatowska
Lucien Corbeel
Teresa Español
Alain Fischer
Magdalena Kurenko-Deptuch
Richard Mouy
Theoni Petropoulou
Joachim Roesler
Reinhard Seger
Marie-José Stasia
Niels H Valerius
Ron S Weening
Baruch Wolach
Dirk Roos
Taco W Kuijpers
Children's Memorial Health Institute · PLEmma Kinderziekenhuis · NLHôpital Necker-Enfants Malades · FRUniversity of Amsterdam · NLHvidovre Hospital · DKInstitut Necker Enfants Malades · FRKarolinska Institutet · SELudwig-Maximilians-Universität München · DEMeir Medical Center · ILNational and Kapodistrian University of Athens · GRSanquin · NLUniversité Joseph Fourier · FRUniversity Children's Hospital Zurich · CHUniversity Hospital Carl Gustav Carus · DEVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CGD is an immunodeficiency caused by deletions or mutations in genes that encode subunits of the leukocyte NADPH oxidase complex. Normally, assembly of the NADPH oxidase complex in phagosomes of certain phagocytic cells leads to a "respiratory burst", essential for the clearance of phagocytosed micro-organisms. CGD patients lack this mechanism, which leads to life-threatening infections and granuloma formation. However, a clear picture of the clinical course of CGD is hampered by its low prevalence (approximately 1:250,000). Therefore, extensive clinical data from 429 European patients were collected and analyzed. Of these patients 351 were males and 78 were females. X-linked (XL) CGD (gp91(phox) deficient) accounted for 67% of the cases, autosomal recessive (AR) inheritance for 33%. AR-CGD was diagnosed later in life, and the mean survival time was significantly better in AR patients (49.6 years) than in XL CGD (37.8 years), suggesting a milder disease course in AR patients. The disease manifested itself most frequently in the lungs (66% of patients), skin (53%), lymph nodes (50%), gastrointestinal tract (48%) and liver (32%). The most frequently cultured micro-organisms per episode were Staphylococcus aureus (30%), Aspergillus spp. (26%), and Salmonella spp. (16%). Surprisingly, Pseudomonas spp. (2%) and Burkholderia cepacia (<1%) were found only sporadically. Lesions induced by inoculation with BCG occurred in 8% of the patients. Only 71% of the patients received antibiotic maintenance therapy, and 53% antifungal prophylaxis. 33% were treated with gamma-interferon. 24 patients (6%) had received a stem cell transplantation. The most prominent reason of death was pneumonia and pulmonary abscess (18/84 cases), septicemia (16/84) and brain abscess (4/84). These data provide further insight in the clinical course of CGD in Europe and hopefully can help to increase awareness and optimize the treatment of these patients.

Indexed as

EuropeFemaleGranulomatous Disease, ChronicHumansMale

Identifiers

PMID19381301
PMCPMC2668749
OpenAlexW2129413349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.